ABM-3249
/ ABM Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 14, 2023
A potent and selective CDK8 inhibitor ABM-3249 with excellent efficacies in multiple in vivo cancer models
(AACR 2023)
- "It also showed an efficacy in a murine colon cancer B16F10 metastasis model. In addition, ABM-3249 displayed a good safety margin in a preliminary tox screen in rodents."
IO biomarker • Preclinical • Acute Myelogenous Leukemia • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • STAT1
1 to 1
Of
1
Go to page
1